TScan Therapeutics (TCRX) Total Current Liabilities (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Total Current Liabilities of $20.0 million for Q1 2026, down 33.02% year-over-year from $29.8 million in Q1 2025, and up 6.82% quarter-over-quarter from $18.7 million in Q4 2025.
TScan Therapeutics (TCRX) Total Current Liabilities (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Total Current Liabilities for 7 consecutive years, with $20.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 33.02% year-over-year to $20.0 million; the TTM figure through Mar 2026 stood at $20.0 million (down 33.02% YoY), while the FY2025 annual figure was $18.7 million, down 48.01% from the prior year.
- Total Current Liabilities rose to $20.0 million in Q1 2026 per TCRX's latest filing, from $18.7 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $38.6 million in Q2 2024 and bottomed at $14.0 million in Q1 2023.
- Historically, Total Current Liabilities has averaged $26.2 million across 5 years, with a median of $29.2 million in 2025.
- Annual changes were most pronounced in 2024 — Total Current Liabilities jumped 124.1% — and 2025, when it tumbled 48.01%.
- TScan Therapeutics' Total Current Liabilities stood at $17.3 million in 2022, then soared by 72.32% to $29.8 million in 2023, then increased by 20.58% to $36.0 million in 2024, then sank by 48.01% to $18.7 million in 2025, then gained by 6.82% to $20.0 million in 2026.
- Business Quant data shows TCRX's Total Current Liabilities at $20.0 million in Q1 2026, $18.7 million in Q4 2025, and $29.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | 30.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.96 Mn |
| Mar 31, 2026 | 19.97 Mn |
| Dec 31, 2025 | 18.70 Mn |
| Sep 30, 2025 | 29.21 Mn |
| Jun 30, 2025 | 31.32 Mn |
| Mar 31, 2025 | 29.82 Mn |
| Dec 31, 2024 | 35.96 Mn |
| Sep 30, 2024 | 28.66 Mn |
| Jun 30, 2024 | 38.57 Mn |
| Mar 31, 2024 | 31.48 Mn |
| Dec 31, 2023 | 29.82 Mn |
| Sep 30, 2023 | 33.15 Mn |
| Jun 30, 2023 | 35.12 Mn |
| Mar 31, 2023 | 14.05 Mn |
| Dec 31, 2022 | 17.31 Mn |
| Sep 30, 2022 | 16.59 Mn |
| Jun 30, 2022 | 17.17 Mn |
| Mar 31, 2022 | 18.47 Mn |
| Dec 31, 2021 | 21.34 Mn |
| Sep 30, 2021 | 22.94 Mn |